Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

Aurelio Cafaro, Antonella Caputo, Claudio Fracasso, Maria T. Maggiorella, Delia Goletti, Silvia Baroncelli, Monica Pace, Leonardo Sernicola, Martin L. Koanga-Mogtomo, Monica Betti, Alessandra Borsetti, Roberto Belli, Lennart Åkerblom, Franco Corrias, Stefano Buttò, Jonathan Heeney, Paola Verani, Fausto Titti, Barbara Ensoli

Research output: Contribution to journalArticlepeer-review


Vaccine strategies aimed at blocking virus entry have so far failed to induce protection against heterologous viruses. Thus, the control of viral infection and the block of disease onset may represent a more achievable goal of human immunodeficiency virus (HIV) vaccine strategies. Here we show that vaccination of cynomolgus monkeys with a biologically active HIV-1 Tat protein is safe, elicits a broad (humoral and cellular) specific immune response and reduces infection with the highly pathogenic simian-human immunodeficiency virus (SHIV)-89.6P to undetectable levels, preventing the CD4+ T-cell decrease. These results may provide new opportunities for the development of a vaccine against AIDS.

Original languageEnglish
Pages (from-to)643-650
Number of pages8
JournalNature Medicine
Issue number6
Publication statusPublished - Jun 1999

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)


Dive into the research topics of 'Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine'. Together they form a unique fingerprint.

Cite this